Sputolysin vet 5 mg/g jauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

sputolysin vet 5 mg/g jauhe

boehringer ingelheim vetmedica gmbh - dembrexine hydrochloride monohydrate - jauhe - 5 mg/g - dembreksiinihydrokloridi

Levocetirizin Ratiopharm 5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

levocetirizin ratiopharm 5 mg tabletti, kalvopäällysteinen

ratiopharm gmbh - levocetirizine dihydrochloride - tabletti, kalvopäällysteinen - 5 mg - levosetiritsiini

Terbinafin Ratiopharm 250 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

terbinafin ratiopharm 250 mg tabletti

ratiopharm gmbh - terbinafine hydrochloride - tabletti - 250 mg - terbinafiini

Valaciclovir Ratiopharm 500 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valaciclovir ratiopharm 500 mg tabletti, kalvopäällysteinen

teva sweden ab - valaciclovir hydrochloride - tabletti, kalvopäällysteinen - 500 mg - valasikloviiri

Metformin ratiopharm 1000 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

metformin ratiopharm 1000 mg tabletti, kalvopäällysteinen

teva b.v. - metformin hydrochloride - tabletti, kalvopäällysteinen - 1000 mg - metformiini

Metformin ratiopharm 850 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

metformin ratiopharm 850 mg tabletti, kalvopäällysteinen

teva b.v. - metformin hydrochloride - tabletti, kalvopäällysteinen - 850 mg - metformiini

Metformin ratiopharm 500 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

metformin ratiopharm 500 mg tabletti, kalvopäällysteinen

teva b.v. - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini

NOBILIS MAREXINE CA 126 VET jäädytetty solususpensio ja liuotin, injektiosuspensiota varten Suomi - suomi - Fimea (Suomen lääkevirasto)

nobilis marexine ca 126 vet jäädytetty solususpensio ja liuotin, injektiosuspensiota varten

intervet international b.v. - kalkkunan herpes simplex-virus tyyppi, elävä kylmäkuivattu - jäädytetty solususpensio ja liuotin, injektiosuspensiota varten - marekin tauti -rokote

Imprida Euroopan unioni - suomi - EMA (European Medicines Agency)

imprida

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - essentiaalisen hypertension hoito. imprida on tarkoitettu potilaille, joiden verenpaine ei laske riittävästi yksinomaan amlodipiinilla tai valsartaanilla.

Imatinib Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

imatinib accord

accord healthcare s.l.u. - imatinibi - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinibi - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. paitsi äskettäin diagnosoitu kroonisen vaiheen kml, ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia. .